Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

Guzi, Timothy J., Paruch, Kamil, Dwyer, Michael P., Labroli, Marc, Shanahan, Frances, Davis, Nicole, Taricani, Lorena, Wiswell, Derek, Seghezzi, Wolfgang, Penaflor, Ervin, Bhagwat, Bhagyashree, Wang, Wei, Gu, Danling, Hsieh, Yunsheng, Lee, Suining, Liu, Ming, Parry, David · 2011 · Molecular Cancer Therapeutics

Abstract

Checkpoint kinase 1 (CHK1) is an essential serine/threonine kinase that responds to DNA damage and stalled DNA replication. CHK1 is essential for maintenance of replication fork viability during exposure to DNA antimetabolites. In human tumor cell lines, ablation of CHK1 function during antimetabolite exposure led to accumulation of double-strand DNA breaks and cell death. Here, we extend these observations and confirm ablation of CHK2 does not contribute to these phenotypes and may diminish them. Furthermore, concomitant suppression of cyclin-dependent kinase (CDK) activity is sufficient to completely antagonize the desired CHK1 ablation phenotypes. These mechanism-based observations prompted the development of a high-content, cell-based screen for γ-H2AX induction, a surrogate marker for double-strand DNA breaks. This mechanism-based functional approach was used to optimize small molecule inhibitors of CHK1. Specifically, the assay was used to mechanistically define the optimal in-cell profile with compounds exhibiting varying degrees of CHK1, CHK2, and CDK selectivity. Using this approach, SCH 900776 was identified as a highly potent and functionally optimal CHK1 inhibitor with minimal intrinsic antagonistic properties. SCH 900776 exposure phenocopies short interfering RNA-mediated CHK1 ablation and interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce dsDNA breaks and cell death in tumor cell backgrounds. Mol Cancer Ther; 10(4); 591–602. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-10-0928

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 171

Metadata

Authors
Guzi, T. J., Paruch, K., Dwyer, M. P., Labroli, M., Shanahan, F., Davis, N., Taricani, L., Wiswell, D., Seghezzi, W., Penaflor, E., Bhagwat, B., Wang, W., Gu, D., Hsieh, Y., Lee, S., Liu, M., & Parry, D.
Venue
Molecular Cancer Therapeutics
Published
2011-04-01
Volume
10
Issue
4
Pages
591-602
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2102815568
Cited by
171
References
3
FWCI
6.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0928
The paper
Guzi, T. J., Paruch, K., Dwyer, M. P., Labroli, M., Shanahan, F., Davis, N., Taricani, L., Wiswell, D., Seghezzi, W., Penaflor, E., Bhagwat, B., Wang, W., Gu, D., Hsieh, Y., Lee, S., Liu, M., & Parry, D. (2011). Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0928

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.